Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Analysts are expecting strong performance driven by the continued success of Lilly's blockbuster medications, particularly the tirzepadine supplier diabetes franchise. However, there are also con